Shi Yan NG

Metabolism and Neurological Diseases
PhD – Stem Cell Biology, National University of Singapore (NUS)

SUMMARY
Shi Yan Ng is currently a Senior Principal Investigator and holds a concurrent appointment as the Associate Director (Education & Training) at  the Institute of Molecular and Cell Biology (IMCB), Agency for Science, Technology and Research (A*STAR).  

After completing her postdoctoral training at Professor Lee Rubin’s laboratory at Harvard University, Shi Yan joined IMCB in 2015 to launch her independent research career, where she studied mechanisms of neurodegenerative diseases using patient-derived induced pluripotent stem cells. 

Shi Yan completed her Bachelor in Science with First Class Honours at the National University of Singapore (NUS) and her PhD with Lawrence Stanton at the Genome Institute of Singapore (GIS), A*STAR, under the NUS Graduate School (NGSS) scholarship.

Shi Yan has won several fellowships and awards for her work, including the L’Oréal for Women in Science National Fellowship (2019), the National Research Foundation (NRF) Fellowship (Class of 2018), the A*STAR International Fellowship (2012), and the Merck Millipore Young Scientist Award (2011).  

AWARDS & GRANTS
  • 2025: National Research Foundation – Competitive Research Programme (NRF CRP)
  • 2023: National Medical Research Council Open Fund – Individual Research Grant (NMRC OF-IRG)
  • 2021: A*STAR-EVX PLATINUM Grant
  • 2021: The SCSS Dr. Susan Lim Award for Outstanding Young Investigator
  • 2020: A*STAR Therapeutics Development Review (TDR) Cycle 5
  • 2019: L'Oréal For Women in Science National Fellowship
  • 2018: National Research Foundation Fellowship (NRFF Class of 2018)
  • 2016: National Medical Research Council Open Fund – Young Individual Research Grant (NMRCOF-YIRG)
  • 2012: A*STAR International Fellowship
  • 2011: Merck Millipore Young Scientist Award

RESEARCH

In developed nations including Singapore, neurological diseases represent one of the top leading causes of death, and the socio-economic burden of these diseases is extremely high. In particular, neurodegenerative diseases such as ALS and dementia have no effective treatments and no cures. My lab's research aims to address these unmet medical needs by:
1) Building disease-relevant cell-based models, including organoids
2) Understanding the molecular and metabolic underpinnings of neurological diseases
3) Discovering and evaluating novel drug targets and therapeutic modalities.

 Current research projects:
1) Investigating the relationship between lipid metabolism defects and astrocyte-mediated toxicity in neurodegeneration
2) Uncovering changes in protein lactylation and its contribution to ALS pathogenesis 
3) Identifying novel microglia-based targets for neurodegeneration using immuno-competent organoids

PUBLICATIONS